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Background: A reduction of ADA2 activity due to autosomal recessive loss of function mutations in CECR1 results in a
newly described vasculopathic phenotype reminiscent of polyarteritis nodosa, with manifestations ranging from fatal
systemic vasculitis with multiple strokes in children to limited cutaneous disease in middle-aged individuals. Evidence
indicates that ADA2 is essential for the endothelial integrity of small vessels. However, CECR1 is not expressed, nor is
the ADA2 protein detectable, in cultured human endothelial cells, thus implicating additional cell types or circulating
factors in disease pathogenesis.
Methods: Considering the phenotypic overlap of ADA2 deficiency with the type I interferonopathy Aicardi-Goutières
syndrome due to mutations in SAMHD1, we looked for the presence of an interferon signature in the peripheral blood
of two newly ascertained ADA2-deficient patients.
Results: We identified biallelic CECR1 mutations in two patients consistent with ADA2 deficiency. Both patients
demonstrated an upregulation of interferon stimulated gene transcripts in peripheral blood. More strikingly however,
genome-wide analysis revealed a marked overexpression of neutrophil-derived genes, suggesting that the vasculitis
seen in ADA2 deficiency may be an indirect effect resulting from chronic and marked activity of neutrophils.
Conclusions: We hypothesise that ADA2 may act as a regulator of neutrophil activation, and that a reduction of ADA2
activity results in significant endothelial damage via a neutrophil-driven process.
Keywords: Adenosine deaminase, ADA2, CECR1, Neutrophil signature, Type I interferon, Aicardi-Goutières syndrome,
SAMHD1Background
Autosomal recessive loss of function mutations in CECR1,
encoding adenosine deaminase 2 (ADA2), were recently
described to cause a variable phenotype encompassing re-
current fevers, livedo reticularis, Raynaud’s phenomenon
and digital necrosis, vascular aneurysms and stenoses, in-
testinal strictures, hepatosplenomegaly and hypogamma-
globulinemia [1,2]. Biopsies of affected tissues revealed an* Correspondence: yanickcrow@mac.com
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unless otherwise stated.inflammatory vasculopathy showing overlap with polyar-
teritis nodosa as a major pathological feature, and signs of
compromised endothelial integrity and endothelial cellular
activation. The precise mechanism leading to disease
remained undefined, but was suggested to relate to a func-
tion of ADA2 as an immune system molecule and/or as a
growth factor.
Here we report two further patients with biallelic muta-
tions in CECR1. In view of a clinical overlap with the Men-
delian type I interferonopathy disease Aicardi-Goutières
syndrome (AGS) due to mutations in SAMHD1, we
searched for an interferon signature in peripheral blood
[3,4]. Both patients demonstrated an upregulation of inter-
feron stimulated gene transcripts. However, more strikingly,
we observed a marked overexpression of neutrophil-relatedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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neutrophils demonstrated increased expression of myelo-
peroxidase compared to controls. Neutrophil counts were
normal. These findings suggests that ADA2 deficiency may
drive unregulated neutrophil activation, and thus play a role
in the activation of endothelial cells and the pathogenesis of
the vasculitis of this devastating disease.
Methods
For Sanger sequencing, primers were designed to amplify
the coding exons of CECR1 (see Additional file 1: Table S1).
Purified PCR amplification products were sequenced using
BigDye™ terminator chemistry and an ABI PRISM 3730
xL Genetic Analyzer (96-capillary system). Mutation de-
scription was based on the reference cDNA sequence
NM_017424.2, with nucleotide numbering beginning from
the first A in the initiating ATG codon.
Methods for the assessment of the expression of a panel
of interferon stimulated genes (ISGs) have been described
previously [4]. Briefly, total RNA was extracted from blood
(peripheral blood mononuclear cells) using a PAXgene
(PreAnalytix) RNA isolation kit. Quantitative reverse tran-
scription polymerase chain reaction (qPCR) analysis was
performed using the TaqMan Universal PCR Master Mix
(Applied Biosystems), and cDNA derived from 40 ng total
RNA. Using TaqMan probes for IFI27 (Hs01086370_m1),
IFI44L (Hs00199115_m1), IFIT1 (Hs00356631_g1), ISG15
(Hs00192713_m1), RSAD2 (Hs01057264_m1), and SIGL
EC1 (Hs00988063_m1), the relative abundance of each tar-
get transcript was normalized to the expression level of
HPRT1 (Hs03929096_g1) and 18S (Hs999999001_s1), and
assessed with the Applied Biosystems StepOne Software
v2.1 and DataAssist Software v.3.01. The median fold
change of the six ISGs, when compared to the median of
29 healthy controls combined, was used to create an inter-
feron score for each patient. RQ is equal to 2-ΔΔCt i.e. the
normalized fold change relative to a control. When a pa-
tient was assayed on more than one occasion, the data for
repeat measurements were combined to calculate a mean
value. The mean interferon score of the controls plus two
standard deviations above the mean (+2 SD) was calculated.
Scores above this value (>2.466) were designated as posi-
tive. Neutrophil-expressed genes were assessed as above
using Taqman probes for MMP8 (Hs01029057_m1), CEA-
CAM6 (Hs03645554_m1), CRISP3 (Hs00195988_m1), LTF
(Hs00914334_m1), DEFA4 (Hs01056651_g1) and LCN2
(Hs01008571_m1). Neutrophil-expressed gene expression
in patients was normalized to expression in 4 healthy con-
trol samples.
RNA quality was checked using the RNA 6000 Nano
Assay, and analyzed on an Agilent 2100 Bioanalyser (Agilent
Technologies). RNA was quantified using a Nanodrop ultra-
low-volume spectrophotometer (Nanodrop Technologies).
Human Genome U133 Plus 2.0 Affymetrix GeneChips wererun according to manufacturers instructions. RNA-Seq data
was generated on a hiSeq 2500 using SENSE mRNA-seq li-
brary Prep kit (Lexogen).
For the microarray analysis, technical quality control and
outlier analysis was performed with dChip (V2005) (http://
www.hsph.harvard.edu/cli/complab/dchip/) [5], using the de-
fault settings. Background correction, quantile normalization,
and gene expression analysis were performed using RMA in
Bioconductor [6].
For the RNA-Seq analysis, quality assessment was per-
formed with FastQC software (http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/). Mapping of reads to the
human transcriptome was done with TopHat software [7]
and transcript assembly and differential expression will be
performed with Cuffdiff of Cufflinks [7]. Read counts were
normalised with DESeq [8].
ADA2 activity in serumwas assessed using a commercial kit
(Diazyme Laboratories) based on the deamination of adeno-
sine to inosine according to themanufacturer’s instructions.
The PerFix-no centrifuge assay Kit from Beckman
Coulter (Hialeah, FL, USA) was used to measure myelo-
peroxidase (MPO) intracellular concentration. Staining of
fresh whole blood was performed using Fluorescein Iso-
ThioCyanate (FITC)-labeled anti-myeloperoxidase (clone
CLB-MPO-1), Phycoerythrin (PE)-labeled anti-lactoferrin
(clone CLB13.17), PE-Texas Red (ECD)-labeled anti-CD62L
(clone DREG56), PE-Cyanine7 (PC7)-labeled anti-CD10
(clone ALB1), APC-Alexa fluor 750 (AA750)-labeled anti-
CD11b (clone Bear1) and Pacific Blue (PB)-labeled anti-
CD16 (clone 3G8). All reagents were purchased from
Beckman Coulter. According to the manufacturer’s instruc-
tions, samples were first fixed with the Fixative Reagent and
incubated for 15 min. Then, aliquots were simultaneously
permeabilized and stained with fluorochrome-conjugated
antibodies. After 35 min of incubation, samples were fixed
using a solution containing formaldehyde. Cytometry ana-
lyses were performed on a NAVIOS flow cytometer using
the NAVIOS software (Beckman Coulter).
The study was approved by a U.K. Multicentre Research
Ethics Committee (reference number 04:MRE00/19) and




This male was the last of five children born to non-
consanguineous parents of European French ancestry.
Of note, an older brother died at the age of 28 years hav-
ing exhibited lifelong inflammatory features including
livedo patterning of the legs, necrotic lesions of the
limbs and multiple cerebral vascular accidents.
Patient 1 presented soon after birth with recurrent ep-
isodes of unexplained fever, together with apthous ul-
cers of the mouth and joint pains. At the age of 11 years
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legs (Figure 1). At this time he experienced a transient
neurological ischemic attack in the context of a febrile
illness. Autoantibody levels (ANCA, ANA, anti-dsDNA)
were negative. He demonstrated a significant IgG defi-
ciency with a slight decrease in IgM and IgA titres. IgE
levels were mildly elevated. Extensive investigations
were otherwise non-contributory. At the age of 12 years
he presented with mononeuritis multiplex (median
nerve, external popliteal nerve), with accompanying in-
dices of systemic inflammation (increased ESR and
CRP). He was treated with oral steroids, but after an ex-
tension of his mononeuritis he subsequently received 6
pulses of monthly cyclophosphamide with partial im-
provement. IVIG replacement therapy was started at
this time.
At the age of 15 years he experienced an acute ab-
dominal crisis requiring surgery. This revealed stenosis
of the ileo-caecum with evidence of a necrotizing vascu-
litis of the small and medium sized vessels evocative of
polyarteritis nodosa (Additional file 1: Figure S1). Soon
thereafter he suffered an acute cerebrovascular accident
resulting in a left-sided hemiparesis. Treatment with
methotrexate and azathioprine was successfully intro-
duced; but both were stopped because of side effects.
Steroids were maintained. He developed a further motor
deficit of the right arm with dysarthria a year later, at
which point ischemic lesions of the left thalamus were
noted on cranial magnetic resonance imaging. The
introduction of rituximab did not prevent the occur-
rence of a further stroke-like episode. Subsequently, he
developed a hemorrhagic lesion of the spleen whist on
anticoagulant therapy. At the age of 21 years he pre-
sented with an intracerebral hemorrhage. Cutaneous
peri-malleolar ulcerative lesions were noted at the age
of 23 years. He was growth retarded with a height of
150 cm (−−2 SDs below the mean).Figure 1 Clinical and radiological features. A-C. Generalized livedo of th
E. Left middle cerebral ischemic stroke. F. Left internal carotid artery stenosPatient 2 (F750)
This male child was born to consanguineous parents of
Pakistani ancestry with no family history of note. Be-
tween the ages of 3 weeks and 2 years he experienced re-
current episodes of dactylitis of both hands mainly
involving the metacarpophalangeal joints. From the age
of 2 years he developed fevers lasting 4–5 days, associ-
ated with a raised CRP and ESR. Erythema nodosum
was noted from the age of 2.5 years on all 4 limbs, but
particularly affecting the legs. Biopsy demonstrated sep-
tal panniculitis.
He complained of intermittent headaches from the age
of 4 years. Against a background of normal development,
at age 6 years he suffered an intracranial hemorrhage
treated with evacuation, leaving him with a right hemiple-
gia and speech impairment. Following the acute event he
continued to have intermittent fever and raised ESR/CRP.
He was also noted to have unexplained hypertension, re-
quiring anti-hypertensive medication, and a vasculitic
rash. Three months later he suffered 2 further acute
neurological events, leaving him with a left and right third
nerve palsy with optic neuritis. Cranial magnetic
resonance imaging demonstrated multiple white matter
abnormalities with linear enhancement and a left
frontal porencephalic cyst. Over time, some of these
lesions resolved and new lesions appeared. Angiography
revealed multiple microaneurysms within the sub-
segmental branches of multiple vessels in the liver, kidneys
and superior mesenteric artery consistent with a
vasculitis-type pattern. At age 6 years, cerebrospinal fluid
(CSF) cells, oligoclonal bands and alpha interferon activity
were normal. CSF pterins demonstrated a normal tetrahy-
drobiopterin and dihydrobiopterin, but an increased neop-
terin of >4 times the upper limit of normal (297 nmol/l:
control 7 – 65).
Considering an inflammatory disorder, he was treated
with intravenous steroids to which he made a positivee back (A), leg (B) and foot (C). D. Right frontal insular haemorrhage.
is.
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opathy, and a settling of his fever and inflammatory
markers. He was then started on steroids, mycopheno-
late mofetil and, as he remained steroid dependent, a
course of cyclophosphamide.
Results
In patient 1, Sanger sequencing revealed compound het-
erozygosity for two variants (c.506G > A, p.Arg169Gln;
c.578C > T, p.Pro193Leu) in CECR1. The Arg169Gln
mutation has been reported previously in the compound
heterozygous state in 3 families [2]. The Pro193Leu is
novel but is considered likely pathogenic on the basis of
conservation and prediction packages and its absence
from publically available control sequence databases
(Additional file 1: Figure S2, Additional file 1: Table S2).
Each parent was heterozygous for one mutation.
Consistent with ADA2 deficiency, ADA2 activity was
markedly decreased in serum (Additional file 1: Figure S3).Figure 2 Gene expression studies. Quantitative reverse transcription PCR
neutrophil-expressed genes in whole blood measured in CECR1 mutation-p
Bar graph showing relative quantification (RQ) values for a panel of six inte
SIGLEC1) and six neutrophil-expressed genes (CEACAM6, CRISP3, DEFA4, LC
positive patients, and two SAMHD1 mutation positive patients, compared t
deviations (i.e. the normalized fold change relative to a calibrator). Each val
to decimalized age at sampling, followed by interferon score calculated fro
of six ISGs. Colors denote individuals, with repeat samples (biological replicWe measured the expression of ISGs in peripheral
blood (Figure 2). Interferon scores of 5.7 and 5.0 were re-
corded at ages 22.48 and 22.56 years respectively. The
patient’s parents, tested on one occasion, did not demon-
strate an interferon signature (interferon score of 0.6 in
the father at age 66 years and 0.4 in the mother at
64 years). Genome-wide expression array showed a
marked upregulation of neutrophil-expressed genes, and
these findings were confirmed on qPCR of a selection of 6
of the most upregulated genes identified in the array data
(Figures 2 and 3). In line with these findings, intracellular
staining revealed an increased expression of MPO in per-
ipheral blood mononuclear (PMN) cells compared to con-
trols (Mean Fluorescence Intensity = 13.5; normal range
[2.9-8]) (Additional file 1: Figure S4). Other markers, in-
cluding lactoferrin, CD10, CD11b, CD16 and CD62L,
were within normal range (data not shown).
In patient 2, Sanger sequencing, revealed a homozy-
gous c.139G > C/p.Gly47Arg mutation in CECR1. This(qPCR) of a panel of six interferon stimulated genes (ISGs) and six
ositive probands, SAMHD1 mutation-positive probands and controls.
rferon stimulated genes (ISGs) (IFI27, IFI44L, IFIT1, ISG15, RSAD2,
N2, LTF, MMP8) measured in whole blood in two ADA2 mutation
o a healthy control. RQ is equal to 2-ΔΔCt, with -ΔΔCt ± standard
ue is derived from three technical replicates. Numbers in brackets refer
m the median fold change in relative quantification value for the panel
ates) denoted by different bars of the same color.
Figure 3 Genome-wide gene expression. Heatmap showing
genome-wide expression array in patients with mutations in CECR1
and RNA-seq analysis in patients with mutations in SAMHD1. Genes
shown had a fold change greater than 5 (mean patients versus
mean controls in the microarrays). Normalised expression levels for
the microarray were expressed as fold change versus control
samples in log scale. Similarly, for RNA-seq, normalised counts were
expressed as fold change versus control samples in log scale. To
generate the heatmap these log ratios (and control values of zero)
were normalised between genes by setting the standard deviation
of each gene to 1. Blue low expression, grey no change, red high
expression. Samples shown: C = control; 1 = F785 patient 1 (ADA2);
2 = F750 patient 2 (ADA2); 3 = F104 (SAMHD1); 4 = F116 (SAMHD1).
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compound heterozygous state in one Turkish patient [9],
and results in the same amino acid substitution as a
Georgian Jewish founder mutation (c.139G > A) de-
scribed previously [1]. This variant has not been seen in
the EVS control database, is highly conserved and is pre-
dicted to be damaging (Additional file 1: Figure S2,
Additional file 1: Table S2). Both parents were heterozy-
gous for the variant. Interferon scores of 5.1, 7.0 and 3.3
were recorded at 6.73, 6.81 and 7.02 decimalised years of
age respectively. Parental samples were not available for
testing. A genome-wide expression array demonstrated
marked upregulation of neutrophil-expressed genes (Fig-
ure 3), and these findings were confirmed on qPCR of a se-
lection of 6 of the most upregulated genes identified in the
array data (Figure 2).
Discussion
Autosomal recessive loss of function mutations in CECR1,
leading to a reduction of ADA2 activity in patient sera, re-
sult in a vasculopathic phenotype reminiscent of polyarteri-
tis nodosa showing highly variable age at onset, severity
and organ involvement, even within families and among
patients with the same mutations. Manifestations range
from fatal systemic vasculitis with multiple strokes in
children, to limited cutaneous disease in middle-aged indi-
viduals. A tendency to aneurysmal and stenosis formation
in the brain, heart, kidney and gut vasculature results in a
substantial risk of both infarction and haemorrhage. In-
flammation was noticed in most patients suggesting that
the underlying mechanism is driven by immune cells [1,2].
The clinical features observed in our patients conform to
the phenotype of ADA2 deficiency already reported, and
include recurrent fevers, livedo reticularis, ulcerative
skin lesions/erythema nodosum, hypogammagobulinae-
mia, gastrointestinal strictures with microaneuryms and
intracerebral vascular disease. We identified compound
heterozygous CECR1 mutations in one patient, includ-
ing a p.Arg169Gln substitution which has been previ-
ously seen in three families. Our second patient was
homozygous for a c.139G > C/p.Gly47Arg mutation.
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the compound heterozygous state in one Turkish pa-
tient, and results in the same amino acid substitution as
a Georgian Jewish founder mutation, indicating the im-
portance of the glycine at position 47 for enzyme activ-
ity (Additional file 1: Figure S5).
In 2009, we identified mutations in SAMHD1 to cause a
subtype of AGS [3], an inflammatory disease of the brain
and skin associated with an upregulation of type I inter-
feron signaling [4]. Clinically, SAMHD1-related AGS dif-
fers from other AGS subtypes in that many patients, more
than 20 described in the literature so far - ranging in age
from neonate to adult, demonstrate a cerebral vasculopa-
thy which can manifest both as stenotic, leading to a
moyamoya appearance, and aneurysmal disease, which
carry a high risk of intracerebral infarction and haemor-
rhage respectively [10-13]. In our experience, patients with
SAMHD1-related intracerebral vascular disease invariably
demonstrate marked peripheral skin involvement, remin-
iscent of the cutaneous lesions described in ADA2 defi-
ciency, with features of a leucocytoclastic vasculitis on
biopsy.
SAMHD1 acts as a deoxynucleoside triphosphate tri-
phosphohydrolase which regulates the intracellular pool
of dNTPs, and hence the production of DNA through
reverse transcription in the cytosol [14]. Patients with
AGS consistently demonstrate an increased expression
of ISGs, a so-called interferon signature, in peripheral
blood [4]. These observations are important in identify-
ing AGS as an inflammatory disorder associated with
the induction of a type I interferon mediated innate im-
mune response, likely driven by endogenously-derived
nucleic acids. It is of note that patients with AGS con-
sistently demonstrate an upregulation of pterins [15], an
inflammatory marker, in the cerebrospinal fluid, a fea-
ture also observed in our patient 2.
Considering the overlap between the ADA2 and
SAMHD1 clinical and radiological phenotypes, we looked
for the presence of an interferon signature in the periph-
eral blood of the two ADA2-deficient patients that we
ascertained. Both demonstrated an upregulation of ISG
transcripts, which was present on all three occasions in
patient 1, and on two occasions in patient 2 when assayed.
More strikingly however, genome-wide analysis revealed a
marked overexpression of neutrophil-expressed genes.
This finding was confirmed on qPCR of a selection of 6 of
the most upregulated genes identified in the array data. In
a previous report, extensive studies of serum cytokines,
and of cytokines produced by cultured peripheral-blood
mononuclear cells, did not demonstrate any convincing
differences between ADA2 deficient patients and controls
[2]. Of note, an analysis of gene expression in peripheral
blood was not reported. Here we show that ADA2 defi-
ciency is associated with a marked upregulation ofneutrophil expressed gene transcripts, which is distinct
from the gene expression pattern seen in another mono-
genic inflammatory vasculitis due to mutations in
SAMHD1.
Conclusion
Previous reports indicate that ADA2 is essential for the
endothelial integrity of small vessels. However, CECR1 is
not expressed, nor is the ADA2 protein detectable, in
cultured human endothelial cells, thus implicating add-
itional cell types, or circulating factors, in the disease
pathogenesis [2]. ADA2 is a secreted molecule which
converts adenosine to inosine and 2′-deoxyadenosine to
2′-deoxyinosine [16,17]. Neutrophils express receptors
for adenosine which can have profound effects on their
function [18]. Our findings suggest that the vasculitis
seen in ADA2 deficiency may be an indirect effect
resulting from chronic and marked activity of neutro-
phils. As one possibility, MPO is a highly abundant neu-
trophil protein that has been recently reported as key
disrupter of endothelial cell function [19]. ADA2 may
act as a plasmatic regulator of PMN cell activation and
prevent MPO expression and subsequent endothelial
damage.
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